Completed PHASE4 INTERVENTIONAL 2-arm NCT00534677

The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed

Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices

Sponsor: Aga Khan University

Conditions Cirrhosis Hematemesis Melena Portal Hypertension

Updated 5 times since 2017 Last updated: Dec 4, 2007 Started: May 31, 2004 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00534677, this PHASE4 trial focuses on Cirrhosis and Hematemesis and remains completed. Sponsored by Aga Khan University, it has been updated 5 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aga Khan University

Data source: Aga Khan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan